ReviewNature reviews. Cancer2011
HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression.
Review in Nature reviews. Cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1,061 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1,061 citing papers in PubMed, 2 syntheses or guidelines pooled it, 1,635 citations in OpenAlex.
- Hypoxia-pyroptosis-associated long noncoding RNAs as prognostic biomarkers in lung cancer: a systematic review and meta-analysis.Respiratory research & clinical practice · 2026Pooled it
- The efficacy and safety of belzutifan inhibitor in patients with advanced or metastatic clear cell renal cell carcinoma: a meta-analysis.BMC pharmacology & toxicology · 2024Pooled it
- Activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrence of glioblastoma.Journal of neuro-oncology · 2023Trial
- Proteomic Analysis Identifies Potential Biomarkers of ELOC -Mutated Renal Cell Carcinoma.The American journal of surgical pathology · 2026Article
- Article
- Pathogenesis of Thyroid Cancer with Particular Emphasis on the Role of AnoikisJournal of clinical research in pediatric endocrinology · 2026Review
- The role of hypoxia-inducible factors in myocardial ischaemia-reperfusion injury and cardioprotection.Nature reviews. Cardiology · 2026Review
- Variants ofLife science alliance · 2026Article
- CLK3 regulates tumor angiogenesis by modulating HIF1α ubiquitination.Cancer gene therapy · 2026Article
- IFN-γ-driven iNOS induction in macrophages mediates CAR T cell resistance in B cell lymphoma.Nature communications · 2026Article
- Applications of synthetic biology in biomedicine.Molecular biomedicine · 2026Review
- Integrated WGCNA, Network Pharmacology, and UPLC-MS/MS Profiling for Investigating the Antitumor Effects of the Kansui Radix Dichloromethane Fraction Against Renal Cell Carcinoma with Experimental Validation.International journal of molecular sciences · 2026Article
- A feedback mechanism between E3 ligase RNF122 and HIF-1α inhibits aggressive behavior in breast cancer.Oncogene · 2026Article
- Smoker's Lungs: Quo Vadis? Exploring the Shared and Individual Smoking-Related Molecular Pathways of Emphysema, Carcinoma, and Fibrosis - An Illustrative Review.Thoracic cancer · 2026Review
- Beyond redox: vitamin C in signaling, epigenetic regulation and protein modification-relevance to cancer therapy.Clinical epigenetics · 2026Review
- Evolutionary convergence and niche-specific regulation of core HIF1A pathway genes synergistically drive divergent hypoxia adaptation in mammals.BMC ecology and evolution · 2026Article
- Loss of Neuropeptide Y Signaling Accompanies the Neural-to-Mesenchymal Transcriptional Transition in Glioblastoma: A Multi-Scale Transcriptomic Analysis.International journal of molecular sciences · 2026Article
- HIF inhibition: Current strategies and clinical challenges.Redox biology · 2026Review
- Understanding how hypoxia contributes to liver cancer stem cells maintenance.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Metabolic pattern changes of macrophages during cancer development and progression.Journal of translational medicine · 2026Review
1,001 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
Hypoxia-inducible factors (HIFs) are broadly expressed in human cancers, and HIF1α and HIF2α were previously suspected to promote tumour progression through largely overlapping functions. However, this relatively simple model has now been challenged in light of recent data from various approaches that reveal unique and sometimes opposing activities of these HIFα isoforms in both normal physiology and disease. These effects are mediated in part through the regulation of unique target genes, as well as through direct and indirect interactions with important oncoproteins and tumour suppressors, including MYC and p53. As HIF inhibitors are currently undergoing clinical evaluation as cancer therapeutics, a more thorough understanding of the unique roles performed by HIF1α and HIF2α in human neoplasia is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.